Back to News

TikaMobile is a Proud Sponsor of Pharma USA 2022

TikaMobile is a Proud Sponsor of Pharma USA 2022

TikaMobile is a proud sponsor of Reuters' Pharma USA conference taking place March 16th-17th in Philadelphia, PA. Our CEO, Manish Sharma, and Senior Director of Client Engagement & Delivery, Hung Khuc, will be presenting on utilizing medical insight & outcomes to drive strategic KOL engagement plans and build meaningful relationships.

The main learning objectives you can expect from this presentation include:

  • How to develop effective strategies and objectives to obtain measurable outcomes for a Medical Affairs Launch Plan
  • Learn how to set up a laser focused strategic imperative, based on medical needs, to determine your outcomes framework
  • Create a strategic plan for MSLs to effectively identify KOLs, maximize engagement, and develop long-term relationships
  • Implement an appropriate system to capture insights and outcomes from KOL interactions to qualitatively showcase the impact of Medical Affairs

We look forward to attending, exhibiting, and presenting at the event and we hope to see you there!

For more information about the event, visit the conference website.

If you’re interested in learning more about TikaMobile, contact us today to schedule a demo.

March 9, 2022

You might also like

October 13, 2026

Pre-Launch Field Medical Starts in Phase 3

The board asks for field medical in the same quarter as the expected approval. The job description, the territory map, and the first advisory board land in one month. The MSLs meet the investigators.

October 7, 2026

How to Evaluate a Medical Insights Platform

Medical affairs insights are only useful when someone can find them later and show what changed because of them. A line that says “HCP positive, send data” cannot be themed, routed, or closed. This.

October 5, 2026

Field Medical Insights: How to Capture What the Visit Meant

The note goes in at 6:40 p.m. It says the visit was positive and that data was requested. By Thursday nobody can say which data, for which patients, or whether the comment challenged the study the.